Philadelphia, Pennsylvania — November 26, 2025 — Leads & Copy — Datavault AI (NASDAQ: DVLT) has finalized the second tranche of its equity financing with Scilex Holding Company (NASDAQ: SCLX), issuing a pre-funded warrant exercisable for 263,914,094 shares of Datavault common stock in exchange for approximately 1,237.6 Bitcoin.
The closing of the second tranche of Scilex’s strategic investment followed approval by Datavault AI’s stockholders at their November 24, 2025, annual meeting. The approval included the issuance of Datavault common stock upon exercise of the pre-funded warrant, and the amendment of Datavault’s certificate of incorporation to increase the number of authorized shares.
This second tranche follows Datavault’s September 26, 2025, closing of the initial tranche, valued at approximately $8 million in Bitcoin. Datavault’s strategic transaction with Scilex is designed to provide growth capital to strengthen Datavault’s digital asset reserves, accelerate its supercomputing infrastructure, support ongoing platform expansion, and unlock new revenue streams.
Datavault granted Scilex a worldwide exclusive license, with the right to sublicense, for the company’s proprietary AI-driven technology. The license is tailored for use within the biotech and biopharma industry, enabling Scilex to create and operate a Biotech Exchange platform. Datavault AI will receive a nonrefundable upfront license fee in four equal installments of $2.5 million each, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. Datavault AI is also eligible for sales milestone payments of up to an aggregate of $2.55 billion upon Scilex achieving certain sales milestones.
Scilex Holding Company CEO Henry Ji, Ph.D., expressed his confidence in the collaboration, noting Datavault AI’s technologies are aligned with the biotech sector’s need for data analytics, AI insights, and supercomputing power.
Datavault AI CEO Nathanial Bradley welcomed Scilex as a major stockholder, stating the Bitcoin tranche validates their shared vision for leveraging digital assets to accelerate capturing market share in the biotech sector.
Datavault AI (Nasdaq: DVLT) specializes in AI-driven data experiences and asset monetization within the Web 3.0 environment, and its cloud platform provides solutions through its Acoustic Science and Data Science Divisions. The Acoustic Science Division features patented technologies for spatial and multichannel wireless HD sound transmission, while the Data Science Division utilizes Web 3.0 and high-performance computing for experiential data perception, valuation, and secure monetization.
Scilex Holding Company is focused on developing and commercializing non-opioid pain management products. Scilex’s commercial products include ZTlido (lidocaine topical system) 1.8%, ELYXYB, and Gloperba. Scilex is headquartered in Palo Alto, California.
Media Inquiries: marketing@dvlt.ai
Investor Contact: 800.491.9665
Corporate Communications: IBN, Austin, Texas, 512.354.7000 Office, Editor@InvestorBrandNetwork.com
Source: Datavault AI
